209 related articles for article (PubMed ID: 30144282)
21. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
[TBL] [Abstract][Full Text] [Related]
22. Lung adenocarcinoma during pregnancy: clinical case and literature review.
Bellido C; Barbero P; Forcén L; Blanco M; Alonso-Riaño M; Galindo A
J Matern Fetal Neonatal Med; 2019 Oct; 32(19):3300-3302. PubMed ID: 29618241
[TBL] [Abstract][Full Text] [Related]
23. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
24. Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung adenocarcinoma in the pleural effusion.
Abe H; Kawahara A; Azuma K; Murakami Y; Takase Y; Naito Y; Akiba J
Diagn Cytopathol; 2018 Sep; 46(9):744-747. PubMed ID: 29637735
[TBL] [Abstract][Full Text] [Related]
25. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
[TBL] [Abstract][Full Text] [Related]
26. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.
Gruber K; Kohlhäufl M; Friedel G; Ott G; Kalla C
J Thorac Oncol; 2015 Apr; 10(4):713-6. PubMed ID: 25789835
[TBL] [Abstract][Full Text] [Related]
27. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
28. [Relationship between expression of anaplastic lymphoma kinase in pleural effusion and clinicopathological features of patients with lung adenocarcinoma and the response to crizotinib].
Mu J; Qu Y; Zhao D; Dong Y; Wang C; Zhang C; Zhang L; Zhang H
Zhonghua Jie He He Hu Xi Za Zhi; 2015 Aug; 38(8):579-83. PubMed ID: 26703339
[TBL] [Abstract][Full Text] [Related]
29. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
30. 'Inflammatory myofibroblastic tumour'-like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
Mason EF; Fletcher CD; Sholl LM
Histopathology; 2016 Sep; 69(3):510-5. PubMed ID: 26880345
[TBL] [Abstract][Full Text] [Related]
31. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
[TBL] [Abstract][Full Text] [Related]
32. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
[No Abstract] [Full Text] [Related]
33. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
[TBL] [Abstract][Full Text] [Related]
34. Uterine cervical metastasis of breast cancer: a rare complication that may be overlooked.
Pauer HU; Viereck V; Burfeind P; Emons G; Krauss T
Onkologie; 2003 Feb; 26(1):58-60. PubMed ID: 12624519
[TBL] [Abstract][Full Text] [Related]
35. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
[TBL] [Abstract][Full Text] [Related]
36. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
38. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
[TBL] [Abstract][Full Text] [Related]
39. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
40. Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.
Marchetti A; Pace MV; Di Lorito A; Canarecci S; Felicioni L; D'Antuono T; Liberatore M; Filice G; Guetti L; Mucilli F; Buttitta F
Lung Cancer; 2016 Sep; 99():11-6. PubMed ID: 27565907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
